Prognostic Impact of Synchronous and Metachronous Second Primary Cancers in Laryngeal Cancer Patients Treated With Radiotherapy: Variable With Time‐Varying Effects and Cox Proportional Hazard Analyses
Asia-Pacific Journal of Clinical Oncology · 2025
DOI: 10.1111/ajco.14206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2025. Verfasst von Akikazu Kobori und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Gifu University Hospital, Gifu City, Gifu, Japan. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, Laryngeal Neoplasms, Neoplasms, Multiple Primary. Die Arbeit nennt 29 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aims
Patients with laryngeal and other head and neck cancers face a high risk of developing second primary cancers. This retrospective cohort study evaluated the prognostic value of second primary cancers in laryngeal cancer patients treated with radiotherapy.
Methods
We retrospectively investigated patients with laryngeal cancer who underwent radiotherapy, and evaluated the incidence and relative risk of synchronous and metachronous second primary cancers in a single‐institution cohort.
Results
Between January 2007 and December 2021, 138 patients with laryngeal cancer were analyzed. The median follow‐up period was 5.2 years. The 5‐year overall survival rate was 82.4% and the progression‐free survival rate was 71.9%. Synchronous and metachronous second primary cancers were observed in 15 (10.9%) and 38 (27.5%) patients, respectively, during the follow‐up period. The cumulative incidence of metachronous second primary cancers was 23.3% at 5 years. Moreover, deaths from laryngeal cancer, other cancers, and noncancer illnesses accounted for 3.6% (5 patients), 12.3% (17 patients), and 10.9% (17 patients), respectively, with most deaths from causes other than laryngeal cancer occurring after the first 5 years. Synchronous second primary cancer was a significant prognostic factor of poor outcomes (hazard ratio, 4.42; 95% confidence interval, 1.93–10.13) on time‐independent multivariate analysis, and metachronous second primary cancer was a significant prognostic factor of poor outcomes (hazard ratio, 4.55; 95% confidence interval, 2.09–9.91) in the time‐dependent Cox proportional hazards model.
Conclusion
Synchronous and metachronous second primary cancers are significant prognostic factors for patients with laryngeal cancer treated with radiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Gifu University Hospital, Gifu City, Gifu, Japan.
- Department of Radiation Oncology, Asahi University Hospital, Gifu City, Gifu, Japan.
- Department of Radiation Oncology, Gifu Prefectural General Medical Center, Gifu City, Gifu, Japan.
- Department of Otorhinolaryngology, Gifu Prefectural General Medical Center, Gifu City, Gifu, Japan.
Zitieren
APA
Kobori, A., Makita, C., Tanaka, O., Okada, S., Kajiura, Y., Yamada, N., & Matsuo, M. (2025). Prognostic Impact of Synchronous and Metachronous Second Primary Cancers in Laryngeal Cancer Patients Treated With Radiotherapy: Variable With Time‐Varying Effects and Cox Proportional Hazard Analyses. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14206
Vancouver
Kobori A, Makita C, Tanaka O, Okada S, Kajiura Y, Yamada N, et al. Prognostic Impact of Synchronous and Metachronous Second Primary Cancers in Laryngeal Cancer Patients Treated With Radiotherapy: Variable With Time‐Varying Effects and Cox Proportional Hazard Analyses. Asia-Pacific Journal of Clinical Oncology. 2025. doi:10.1111/ajco.14206
BibTeX
@article{Kobori2025,
author = {Kobori, Akikazu and Makita, Chiyoko and Tanaka, Osamu and Okada, Sunaho and Kajiura, Yuichi and Yamada, Nansei and Matsuo, Masayuki},
title = {Prognostic Impact of Synchronous and Metachronous Second Primary Cancers in Laryngeal Cancer Patients Treated With Radiotherapy: Variable With Time‐Varying Effects and Cox Proportional Hazard Analyses},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2025},
doi = {10.1111/ajco.14206}
}
EUVIMED